Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy

Authors


L. G. Durrant, Academic Department of Clinical Oncology, School of Molecular Sciences, University of Nottingham, City Hospital Campus, Nottingham NG5 1PB, UK. E-mail: lindy.durrant@nottingham.ac.uk

Summary

OTHER THEMES PUBLISHED IN THIS IMMUNOLOGY IN THE CLINIC REVIEW SERIES

Metabolic Diseases, Host Responses, Allergies, Autoinflammatory Diseases, Type 1 diabetes and viruses.

Research into aberrant glycosylation and over-expression of glycolipids on the surface of the majority of cancers, coupled with a knowledge of glycolipids as functional molecules involved in a number of cellular physiological pathways, has provided a novel area of targets for cancer immunotherapy. This has resulted in the development of a number of vaccines and monoclonal antibodies that are showing promising results in recent clinical trials.

Ancillary